What is ACP-01?
ACP-01 is an autologous cell therapy derived from the patient’s own blood, developed for the regeneration of ischemic tissue. Clinical data show up to 27% improved heart function and 93.5% avoidance of amputations in CLTI.
What stage is the program in?
Clinically active – Phase II data, expansion into vascular dementia through partnership with FireFly Neuroscience (AI monitoring). Approval in Germany (TERMIS 2025) and private placement signals progress.
How does Hemostemix finance itself?
Capital sources include participation by PatentVest, private placement in spring 2025 (≈ USD 336,500), and sale of convertible bonds (USD 517,230), with a focus on financing until the end of the phase.
What is the financial situation?
End of 2024: Cash CA$705,700, annual loss CA$2.6M, deficit CA$65.9M, working capital deficit CA$1.78M. “Going concern” note indicates capital requirements for further growth.
Receive exclusive updates on exciting commodity companies, market analyses, and investment opportunities directly in your inbox.
By submitting the form, you agree that your contact details will be processed for sending the newsletter.
Stay up to date: Our GOLDINVEST newsletter regularly informs you about current company news, market analyses, and exciting investment opportunities from the world of commodities.
Track the current price developments of key commodities such as gold, silver, copper, and lithium – including charts, market commentaries, and historical trends.
Here you will find in-depth background knowledge on commodities, markets, and exploration companies – concisely explained and easy to understand for beginners and professionals.
Our glossary explains key terms from the world of commodities, stock exchange, and exploration – ideal for quick reference and better understanding of our articles.
The leading platform for commodity news, market analyses, and company reports in the German-speaking region.
Copyright © 2025. GOLDINVEST Consulting GmbH. All rights reserved.
